How we create value
We bring to the biotechnology and pharmaceutical industries the power to discover new and better drugs in a more effective way
Our in silico NDD platform can benefit traditional pharmaceutical and biotechnology companies that are looking to decrease the cost and increase the speed and productivity of their drug discovery activities. We can apply our NDD platform to disease areas of mutual interest or unlock inherent value within partners' existing proprietary datasets.
Given the productivity of the platform, we are also developing internal, preclinical drug discovery programmes to a point where they are attractive to industrial partners looking to acquire or in-license such assets.
We understand that our NDD platform is at the core of how we create value and therefore we are continuously updating and improving it so that we can offer a unique combination of convergent technologies.